公司资料
Blueprint Medicines 股价、新闻与催化剂
- 股票代码:
- BPMC
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股价为何变动
Current closing-price context is not available for BPMC.
公司概览
业务概览
Blueprint Medicines is a precision-oncology and rare-disease company with a strong focus on kinase biology and mast-cell disease.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ, Blueprint sits in targeted-therapy biotechnology.
商业模式特征
Its model combines commercial product growth, targeted oncology development, and continued investment in rare-disease programs.
生物医药行业定位
Blueprint is a high-quality targeted-therapy biotech whose stock reacts to launches, data, and strategic optionality.
未来催化剂
- Blueprint Medicines's catalysts are Ayvakit in systemic mastocytosis and BLU-808 as the next immunology growth option. The market will care about whether the mast-cell franchise can keep expanding while the next program de-risks the pipeline.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。